Department of Diagnostic Imaging (C.M.P., G.B.), and Department of Endocrinology (I.M., E.P.), Regina Apostolorum Hospital, 00041 Albano Laziale, Italy; Department of Diagnostic Imaging and Interventional Oncology Unit (G.M.), Circolo Hospital of Busto Arsizio, 21052 Busto Arsizio, Italy; Cervico-Facial Ultrasound Diagnostic and Interventional Unit (G.A.), Institute of Oncology, 70126 Bari, Italy; Endocrinology Unit (D.B.), Azienda S.L.6 Livorno, 46080 Livorno, Italy; Department of Internal Medicine (P.D.F., G.G.), University of Perugia, 06100 Perugia, Italy; Institute of Biochemistry and Clinical Biochemistry (E.D.S.), Catholic University "Sacro Cuore," 00168 Rome, Italy; Endocrinology Unit (R.E.), S. S. Annunziata Hospital, 50121 Cosenza, Italy; Endocrinology Unit (B.R.), Atri Hospital, 87071 Atri, Italy; Department of Endocrinology (T.R., P.V.), University of Pisa, 56127 Pisa, Italy; and Department of Interventional Radiology (G.L.P., S.D.), Pesenti-Fenaroli Hospital, 24022 Alzano Lombardo, Italy.
J Clin Endocrinol Metab. 2015 Oct;100(10):3903-10. doi: 10.1210/jc.2015-1964. Epub 2015 Aug 14.
Image-guided laser ablation therapy (LAT) of benign thyroid nodules demonstrated favorable results in randomized trials with fixed modalities of treatment. The aim of this retrospective multicenter study was to assess the effectiveness, tolerability, and complications of LAT in a large consecutive series of patients from centers using this technique in their routine clinical activity.
Clinical records of 1534 consecutive laser-treated nodules in 1531 patients from eight Italian thyroid referral centers were assessed. Inclusion criteria were as follows: solid or mixed nodules with fluid component up to 40%; benign cytological findings; and normal thyroid function.
LAT was performed with a fixed-power protocol, whereas the number of applicators and illumination times were different according to target size. From one to three illuminations with pullback technique and with a total energy delivery based on the nodule volume were performed during the same session. Patients were evaluated during LAT, within 30 days, and 12 months after the procedure.
Total number of treatments was 1837; 1280 (83%) of nodules had a single LAT session. Mean nodule volume decreased from 27 ± 24 mL at baseline to 8 ± 8 mL 12 months after treatment (P < .001). Mean nodule volume reduction was 72% ± 11% (range 48%-96%). This figure was significantly greater in mixed nodules (79% ± 7%; range 70%-92%) because they were drained immediately before laser illumination. Symptoms improved from 49% to 10% of cases (P < .001) and evidence of cosmetic signs from 86% to 8% of cases (P < .001). Seventeen complications (0.9%) were registered. Eight patients (0.5%) experienced transitory voice changes that completely resolved at the ear-nose-throat examination within 2-84 days. Nine minor complications (0.5%) were reported. No changes in thyroid function or autoimmunity were observed.
Real practice confirmed LAT as a clinically effective, reproducible, and rapid outpatient procedure. Treatments were well tolerated and risk of major complications was very low.
在采用固定治疗模式的良性甲状腺结节的图像引导激光消融治疗(LAT)随机试验中,取得了良好的效果。本回顾性多中心研究的目的是评估在采用这种技术的意大利 8 个甲状腺转诊中心的常规临床实践中,对大量连续患者进行 LAT 的有效性、耐受性和并发症。
评估了来自意大利 8 个甲状腺转诊中心的 1531 例患者的 1534 个连续激光治疗结节的临床记录。纳入标准如下:实性或混合性结节,伴 40%以内的液性成分;良性细胞学检查结果;甲状腺功能正常。
采用固定功率方案进行 LAT,而根据目标大小,使用的探头数量和照射次数不同。在同一次治疗中,采用拉回技术进行 1 到 3 次照射,并根据结节体积输送总能量。在 LAT 期间、治疗后 30 天和 12 个月对患者进行评估。
总治疗次数为 1837 次;1280 个(83%)结节进行了单次 LAT 治疗。结节体积从基线时的 27 ± 24 mL 减少到治疗后 12 个月时的 8 ± 8 mL(P <.001)。结节体积减少率为 72% ± 11%(范围为 48%-96%)。混合性结节的减少率明显更大(79% ± 7%;范围为 70%-92%),因为它们在激光照射前立即被排空。症状从 49%改善至 10%(P <.001),美容体征从 86%改善至 8%(P <.001)。记录到 17 种并发症(0.9%)。8 例患者(0.5%)出现短暂性声音改变,在耳鼻喉科检查中 2-84 天内完全恢复。报告了 9 例轻微并发症(0.5%)。未观察到甲状腺功能或自身免疫的变化。
实际实践证实,LAT 是一种临床有效、可重复且快速的门诊治疗方法。治疗耐受性良好,严重并发症的风险非常低。